Tamaro S. Hudson, PhD, is an associate professor of pharmacology at Howard University College of Medicine. Dr. Hudson is a molecular pharmacologist with expertise in cancer, natural products, molecular biology, and pharmacogenetics. He has integrated his research focus by identifying novel signature biomarkers with the evaluation of new chemopreventive cancer strategies, which have been evaluated in Phase I and Phase II clinical trials. His expertise in cancer-related processes, specifically mitochondrial health, which is critical in neurodegenerative diseases, has allowed him to transfer these skills to Fragile X-associated tremor/ataxia syndrome (FXTAS). Currently, his lab assesses the biological activity of natural compounds on mitochondrial health in FXTAS. His research interests continue to expand in order to build collaborations across broad disciplines.

Dr. Hudson served on the board of the Maryland Fragile X Resource Group. His personal experience with this syndrome and current research interest in FXTAS led Dr. Hudson to join the advisory committee for the International Fragile X Premutation Registry.